Skip to content
Open access

14 Evaluation of the Effects of the HIF-2α Inhibitor Belzutifan on T-cell–Mediated Cytotoxicity in Renal Cell Carcinoma

Sep 2026 · The Oncologist · Vol 31 · 0 citations

TL;DR

An in vitro RCC antigen model system was established to evaluate the impact of belzutifan on T-cell cytotoxicity and revealed that IL-2 and IFNG were among the most significantly downregulated genes in HIF2α knockout T cells.

Abstract

Abstract Background Renal cell carcinoma (RCC) is characterized by a hypoxic tumor microenvironment that recruits immunosuppressive macrophages and regulatory T cells to suppress anti-tumor immunity. Belzutifan, a hypoxia-inducible factor 2 alpha (HIF-2α) inhibitor recently approved by the FDA, significantly improves progression-free survival in patients with previously treated, advanced RCC (LITESPARK-005 trial). Belzutifan is now being evaluated in combination with immune checkpoint inhibitors (ICI) in multiple phase III trials. However, preclinical murine data suggests that hypoxia signaling is important for effector T-cell function (Doedens, et al. Nat Immunol. 2013), raising the concern that pharmacologic HIF-2α inhibition might impair anti-tumor immunity. It remains unclear whether belzutifan has an impact (either positive or negative) on human T cell function, particularly anti-tumor cytotoxic activity. Therefore, we established an in vitro RCC antigen model system to evaluate the impact of belzutifan on T-cell cytotoxicity. Methods T cells were isolated from healthy donor peripheral blood mononuclear cells (PBMCs). HIF2α knockout (KO) T cells were generated using a CRISPR-Cas9 RNP electroporation, and they were stimulated with anti-CD3/CD28 beads for 48 hours under normoxic or hypoxic (1% O2) conditions. RT-qPCR and bulk RNA sequencing were used for transcriptomic analysis of the T cells. PBMCs were also genetically modified to express an HLA-A*02:01-restricted NY-ESO-1–specific T-cell receptor, thereby generating antigen-specific T cells for the cytotoxicity assay. These T cells were pretreated with belzutifan for 48 hours under hypoxia. The human VHL-mutated RCC cell line 786-O (parental HLA-A03:01) was utilized as the target cell population. Endogenous HLA class I expression was knocked out using the CRISPR–Cas9 system. Subsequently, the cells were transduced with a lentiviral vector encoding HLA-A02:01, CTAG1B (NY-ESO-1), and HIF-2α (either wild-type or the belzutifan-resistant G323E variant), generating the 786-O-WT and 786-O-G323E cell lines. As the G323E substitution interferes with belzutifan binding to HIF-2α, any differences observed in cytotoxicity assays can be attributed to effects of belzutifan on T cells rather than direct cytotoxic effects on 786-O-G323E tumor cells. RCC target cells were labeled with CellTrace Far Red and subsequently co-cultured with the T cells at effector-to-target (E:T) ratios of 0:1 or 1:1 for 12 hours. Cytotoxic activity was assessed by flow cytometry using Annexin V and propidium iodide staining, with analysis restricted to doublet-excluded, CellTrace-positive target tumor cells. Specific lysis (%) was calculated according to the formula: (1 − [viability at E:T = 1:1] / [viability at E:T = 0:1]) × 100. Statistical significance was evaluated using two-sided paired t-tests. Results HIF2α mRNA expression markedly increased in T cells upon stimulation under hypoxic conditions. Differential gene expression analysis of bulk RNA sequencing revealed that IL-2 and IFNG were among the most significantly downregulated genes in HIF2α knockout T cells, with log2 fold changes of –4.08 and –2.13, and adjusted p-values of 3.1 × 10⁻¹¹ and 5.5 × 10⁻²0, respectively. In contrast to genetic KO, pharmacologic HIF2a inhibition with belzutifan did not impair T-cell function. In fact, T cells preconditioned with belzutifan demonstrated modestly increased specific lysis of both 786-O-G323E and 786-O-WT target cells compared with DMSO-treated controls (p = 0.0385 and p = 0.0256, respectively). These findings indicate that belzutifan may augment T-cell–mediated cytotoxic activity. Conclusions Although HIF2α is strongly upregulated under hypoxia and T cell stimulation, and its genetic deletion reduces cytokine gene expression, short-term pharmacologic inhibition does not impair antigen-specific T-cell cytotoxicity against RCC target cells within a hypoxia-modeled antigen system. These data support the biological plausibility of combining belzutifan with immune checkpoint inhibitors (ICIs) as a therapeutic strategy in RCC.

Read PDF

Similar papers

Open access Sep 2026

24 A Phase 1b/2 Study of Abemaciclib Plus Cabozantinib in Immune Checkpoint Blockade-Pretreated Metastatic Clear Cell Renal Cell Carcinoma and Translocation-Associated Renal Cell Carcinoma (NCT06835972)

Abstract Background There is a need for novel systemic therapies in patients with metastatic renal cell carcinoma (RCC) who progress on standard agents. A hallmark of clear cell RCC (ccRCC) is von Hippel Lindau (VHL) inactivation which affects downstream targets including vascular endothelial growth factor (VEGF). It a...

Sahil D. Doshi, Y. Ged, Andrea Knezevic et al. · 0 citations
Open access Aug 2026

Combination therapy with Nifuroxazide and Lenvatinib exerts superior anti-hepatocellular carcinoma effect by enhancing the anti-tumor immune response

Background Lenvatinib is a first-line multi-target tyrosine kinase inhibitor for hepatocellular carcinoma (HCC) that exerts anti-angiogenic effects by blocking VEGF signaling. However, its clinical efficacy is often compromised by adaptive resistance. Nifuroxazide, an anti-diarrheal agent, has been identified by our gr...

Jing Yang, Jia-Xin Geng, Yue-Ling Yin et al. · 0 citations
Open access Sep 2026

Interleukin-33 alleviates the immunosuppressive tumor microenvironment and enhances anti-programmed death ligand-1 immunotherapy efficacy in hepatocellular carcinoma

Abstract Background: Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide. The immunosuppressive tumor microenvironment (TME) and limited response to immune checkpoint blockade (ICB) therapy remain major obstacles to improving HCC prognosis. Interleukin-33 (IL-33) is a multifunctional cytokin...

En-Si Ma, Yan-Ge Gu, Wei-Qiao He et al. · 0 citations
Sep 2026

Abstract B047: CXCR4 synergizes with multi-RAS inhibition by overcoming T cell exclusion to enhance immunogenic cancer cell death in human pancreatic cancer slice culture

The multi-RAS inhibitor, daraxonrasib, has demonstrated a remarkable improvement in outcomes for patients with metastatic PDAC. Pre-clinical murine studies have shown that the durable effects of the pre-clinical multi-RAS inhibitor, RMC-7977, require an intact immune system including CD8+ T cells and cross-presen...

Sheela R. Damle, Nancy Liu, Xiu-Yun Jiang et al. · 0 citations
Review Open access Sep 2026

Immunosuppressive cell populations as potential drivers of extrinsic immune checkpoint inhibition resistance in clear cell renal cell carcinoma

Clear cell renal cell carcinoma (ccRCC) is an immunogenic cancer in which the use of Immune checkpoint inhibitors (ICIs) has provided clinical benefit. However, long-term therapeutic benefit is limited, as some do not respond initially while others develop resistance after treatment. Although extensive studies have bee...

Usman Humayun Temuri · 0 citations
Open access Aug 2026

Exploration of the regulatory mechanism of PD-L1 expression in pMMR AGS gastric cancer cell by cytotoxic drugs and anti-angiogenic drugs

It is demonstrated that cytotoxic drugs and the anti-angiogenic drug(apatinib) effectively inhibited the proliferation of pMMR-type AGS gastric cancer cells and may also have the potential to upregulate PD-L1 mRNA and protein expression in pMMR-type AGS gastric cancer cells.

Jinming Li, M. Da, Xue-Ying Zhou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.